Amazon Web Services (AWS) is collaborating with EvolutionaryScale, an AI company, to provide access to ESM3 language models for drug discovery. EvolutionaryScale recently secured $142 million in funding with support from AWS and NVIDIA. ESM3 allows scientists to create new proteins and streamline protein design workflows. AWS customers can access the open-source version of ESM3 on Amazon SageMaker and AWS HealthOmics. Google also announced an LLM for drug discovery and therapeutic development called Tx-LLM, which uses SMILES strings to represent molecules. The HIMSS AI in Healthcare Forum in Boston is set for September 5-6.
Source link
AWS partners with EvolutionaryScale following its $142M raise
